Kornimate/medical-research-clean huggingface dataset:
the effect of high-intensity laser therapy on the supraspinatus tendon using shear wave elastography

Conditions: Subacromial Impingement Syndrome

Summary: subacromial impingement syndrome, one of the most common causes of shoulder pain. in studies investigating the effectiveness of high-intensity laser in patients with subacromial impingement syndrome, it was stated that high-intensity laser reduced the complaints of patients in the early and late periods. however, there is no research examining the effect of high-intensity laser on the supraspinatus tendon. therefore, the investigators aimed to investigate the effect of high-intensity laser on the supraspinatus tendon using shear wave elastography.

subacromial impingement syndrome, one of the most common causes of shoulder pain, occurs when the supraspinatus tendon, subacromial bursa or bicipital tendon becomes compressed between the acromion, coracoacromial ligament, coracoid process and/or acromioclavicular joint during shoulder movements. several factors contribute to subacromial impingement syndrome, including weakening of the rotator cuff, capsular tension, poor scapulohumeral rhythm, and muscular imbalance in the upward rotation force of the scapula. steroid and non-steroidal anti-inflammatory agents, physiotherapy applications, laser therapy, manual therapy, eswt and active and passive normal joint movements involving the shoulder joint are frequently applied treatments in the treatment of subacromial impingement syndrome. it is stated that high-intensity laser treatment can quickly produce photochemical and photothermic effects in deep tissue. therefore, collagen production in tendons is promoted and blood flow, vascular permeability and cell metabolism can be increased. as a result of all these processes, tissue healing begins and painful stimuli decrease. in studies investigating the effectiveness of high-intensity laser in patients with subacromial impingement syndrome, it was stated that high-intensity laser reduced the complaints of patients in the early and late periods. however, there is no research examining the effect of high-intensity laser on the supraspinatus tendon. therefore, in this study, the investigators aimed to investigate the effect of high-intensity laser on the supraspinatus tendon using shear wave elastography.

Eligibility criteria:
inclusion criteria: * shoulder pain lasting more than 6 weeks. * diagnosed with subacromial impingement * being between the ages of 30-60 * volunteering to participate in the study exclusion criteria: * acute inflammatory disease affecting the shoulder area * presence of cervical radiculopathy * surgical intervention involving the shoulder and neck area * soft tissue or bone problems affecting the shoulder * had any neurologic problems * patients who wish to withdraw from the study at any stage after volunteering

Keywords: elasticity imaging techniques physical therapy modalities rotator cuff
methylene blue treatment of covid-19

Conditions: SARS-CoV2

Summary: despite enormous progress in understanding covid-19, there is little evidence that a solution, therapeutic or preventive, is close to being achieved. repurposing of well known, widely available drugs represent an attractive approach to speed up availability of active treatments. such substances as i.e. hydroxychloroquine and others, are already under investigation and in widespread off label use. for many reasons methylene blue (mb), the oldest synthetic substance in medicine (1876 synthesized by basf) is such a promising candidate for an active treatment against sars-cov-2 infected people and for covid-19 patients.


Eligibility criteria:
inclusion criteria are: * signed informed consent * age ≥ 18 years * microbiologically confirmed sars-cov-2 infection * negative pregnancy test in women of child-bearing age exclusion criteria are: * documented refusal to participate in the study * known g-6-phophatase deficiency * treatment with a serotoninergic drug
eternals: remote monitoring in lung cancer patients

Conditions: Non-small Cell Lung Cancer; Remote Monitoring; Mobile Health; Chemotherapy Effect

Summary: the primary objective of this project is to determine the feasibility of an integrated remote monitoring system in the routine care of lung cancer patients receiving cytotoxic chemotherapy.

lung cancer is a highly prevalent malignant tumor with 5.563 new cases in belgium in 20201. up to 70% of patients present with locally advanced or metastatic disease at diagnosis 1. most of these patients require systemic therapy including cytotoxic chemotherapy as part of their treatment plan. the mortality rate in this patient population remains high due to the aggressive nature of the disease, but also due to treatment related toxicities such as dehydration, infection, and anemia, resulting in emergency department (ed) visits and rehospitalizations. routine administration of highly effective anti-emetics and the use of granulocyte colony-stimulating growth factors greatly reduced the complication rate in these patients 2, 3. also, remote symptom monitoring using a web-based tool to which patients can self-report their toxicities (i.e., patient-reported outcomes; pros) had a marked impact on reducing ed visits and increasing overall survival in the patient-reported outcome (pro) group 4-6. despite these successes there is still a large proportion of lung cancer patients for whom weekly self-reports are not feasible. more specific: low socio-economic status, elderly patients and social isolation are associated with low compliance 7, 8. the latter lung cancer patient subgroup is at the highest risk of under-detection when presenting with treatment- or disease-related toxicity. the investigators hypothesize that implementation of an integrated remote monitoring system tracking heart rate, heart rate variability, body temperature, respiration rate, nocturnal oxygen saturation, sleep tracking and daily activity level via an unobtrusive wearable device is more performant and less burdensome compared to other self-reporting methods (e.g., pros). the primary aim of this project is to set up and implement an integrated remote monitoring system in the routine care of lung cancer patients receiving cytotoxic chemotherapy, in which the remote monitoring is enabled via an unobtrusive wearable device. via this innovative implementation the investigators believe that patient care can be drastically improved due to the earlier detection of deterioration (i.e., less rehospitalizations and ed visits), especially for those high-risk frail patients.

Eligibility criteria:
inclusion criteria:- * patient must be in the possession of a phone * diagnosis of stage iv lung cancer patients treated with cytotoxic chemotherapy * older than 18 years of age exclusion criteria: * life expectancy of less than 6 weeks * not able to understand the dutch language
lower tourniquet pressure study

Conditions: Hand Injuries; Upper Extremity Injury

Summary: this study design is a prospective, double-blinded, randomized controlled trial evaluating the quality of bloodless surgical field with lower tourniquet pressures based on systolic blood pressure (sbp) compared to standard tourniquet pressures. a secondary goal is to evaluate the effect of lower tourniquet pressures on post-operative tourniquet site pain. the rationale behind the study is to provide evidence-based guidelines on tourniquet use to continue providing quality surgical care while minimizing pain and potential harm to patients.

patients undergoing hand and upper extremity surgery at our institution will be offered participation in this study. consenting patients will be randomized in a double-blinded fashion to either standard tourniquet pressure of 250 mmhg or lower tourniquet pressures based on sbp. demographic data will be recorded as well as details of the surgical procedure. post-operatively, the operating surgeon will complete a questionnaire about the quality of bloodless surgical field and the patient will complete a questionnaire about post-operative pain. this study will enroll approximately 150 patients. statistical analysis will be completed to analyze the effectiveness of the intervention.

Eligibility criteria:
inclusion criteria: * adult patient age 18 or older * undergoing hand or upper extremity procedure * tourniquet is used for procedure * willingness and ability to consent exclusion criteria: * individuals with procedures that are over 120 minutes in length
efficacy and safety of continuous infusion of ketamine in pediatric intensive care unit (kiss study)

Conditions: Analgesia; Ketamine Toxicity; Bronchospasm; Sedation Complication

Summary: this study, prospectively evaluate the efficacy and safety of ketamine administered in continuous infusion lasted more than 12 hours in children admitted to pediatric intensive care unit of padova. this drug may be used as adopted as adopted as adjuvant to analgesia and sedation or as adjuvant to bronchospasm therapy. the investigators evaluated efficacy considering the sparing of other analgesics and sedatives and the level of sedation after ketamine infusion for the first use and the sparing of other bronchospasm drugs sedative dosage for the second use. to evaluate safety the investigators considered the presence of adverse effects and onset of withdrawal and delirium syndrome. the study will included al least 55 pediatric patients \< 18 years and mechanically ventilated.

ketamine is an n-methyl-d-aspartate-receptor-antagonist commonly used over the last decades as an anesthetic and analgesic agent for procedural sedation. the use of ketamine as a prolonged infusion was first described in 1990 and a prolonged infusion of ketamine has been described as a successful strategy for analgesia and sedation in patients with hemodynamic instability, in patients who were mechanically ventilated and poorly responsive to conventional drugs. an other indication for ketamine infusion is the presence of bronchospasm, due to its action in promoting bronchodilatation. however, existing studies on ketamine for prolonged sedation are mainly retrospective and include small sample size, suggesting that this topic needs to be further investigated. the aim of this observational single center study is to describe the use of ketamine used as adjuvant to conventional analgesic and sedative strategy (opioid and benzodiazepine in continuous infusion) as prolonged infusion (i.e. ≥ 12 hr) in pediatric patients. the investigators will evaluate ketamine indications, dosages, infusion duration, adoption of boluses, modality of weaning. concomitant analgesic and sedative management and monitoring of level of sedation (using a validated scale) are considered measures of efficacy. sparing of other bronchospasm drugs sedative dosage are considered measures of efficacy if ketamine is used in patients with obstructive respiratory diseases. presence of adverse effects (including withdrawal syndrome symptoms and delirium) during infusione or 48 hours after weaning are considered measures of safety. data were collected using a standardized data sheet. the study lasted 18 months to reach a numerosity of 55 patients. all the requested institutional approvals were collected before starting the data collection.

Eligibility criteria:
inclusion criteria: * pediatric intensive care unit admission * mechanical ventilation * ketamine infusion \> 12 hours exclusion criteria: * parents refusal to participate

Keywords: pediatric intensive care unit ketamine sedation
use massive parallel sequencing and exome capture technology to sequence the exome of fanconi anemia children and their patents

Conditions: Fanconi Anemia; Autosomal or Sex Linked Recessive Genetic Disease; Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases.; Hematopoiesis Maintainance.

Summary: fanconi anemia is a rare autosomal or sex linked recessive genetic disease. the disease is characterized by bone marrow hematopoiesis failure, multiple congenital abnormalities, and susceptibility to neoplastic diseases. the cells of fa patients are extremely sensitive to mmc and deb. the symptoms and ages of fa patients are different, so by comparing the exome of fa patients and their parents, the mutations that were accumulated in fa patients could be found, and these genes might be sensitive to repairment and be important for hematopoiesis maintainance.

heterogeneity of fa. in the research of animal model, the phenotypes of fanca, fancc and fancg knockout mice are similar. they grow up and develop normally, without any severe blood disease or tumor. however, they show chromosome instablity and highly sensitivity to mmc. and they have gonadal dysfunction and fertility defects. from this we conclude that the severe physical deformity of fa patients might be induced by other mutations. by comparing among the fa patients and between fa patiens and normal people, we look forward to find the mutated genes and verify their relationship with the physical deformity. even in 90% of fa patients the bone marrow failure will eventually occur, but the starting age ranges from 8-84. and immuno-inhibition therapy has no effects on fa. other dna repair dysfunction diseases have higher rate of tumor, but not so high rate of bone marrow failure as fa does, which implies that the fa protein has the key role in hematopoietic stem cell maintainance. in fancc-/- mice, young mice is insensitive to dna crosslinks with comet assay, but not adult mice, indicating that the accumulation of dna damage during time leads to dna repairment defects. by comparing the exome of fa patients and their parents, the mutations that were accumulated in fa patients could be found, and these genes might be sensitive to repairment and be important for hematopoiesis maintainance.

Eligibility criteria:
inclusion criteria: all the children that are diagnosed to be fa patients at the blood disease hospital between 08/01/2010 - 07/31/2011, will be asked to participated in this study after acquiring the consent. exclusion criteria: can not acquiring content

Keywords: fanconi anemia hematopoiesis maintainance
impact of chronic pulmonary aspergillosis (cpa) on health status and well-being

Conditions: Chronic Pulmonary Aspergillosis

Summary: to develop and validate a novel disease-specific questionnaire for measuring hrqol in patients with chronic pulmonary aspergillosis (cpa-haq) for use in clinical research, including clinical trials.


Eligibility criteria:
inclusion criteria: 1. all patients \>/= 18 years old and able to provide informed consent 2. patients with a diagnosis of chronic pulmonary aspergillosis 3. to speak and understand english 4. able to provide informed consent

Keywords: cpa
influence of the vitreomacular interface on the progression of the diabetic macular edema after anti-vegf injection

Conditions: Diabetic Macular Edema; Vitreomacular Interface; Anti-VEGF Treatment

Summary: influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors


Eligibility criteria:
inclusion criteria: * diabetic macular edema treatable with antiangiogenic drugs exclusion criteria: * age under 18 * cardiovascular events during the last year * previous vitrectomy * previous macular edema treatment during the last 4 months
effect of neck vs. combined neck-lumbar mobilization on pain and motion in cervical disc herniation

Conditions: Cervical Disc Herniation

Summary: background to assess the effectiveness of kaltenborn-evjenth orthopedic manual therapy (keomt) applied to cervical-only mobilization versus both lumbar and cervical regions on pain intensity and range of motion (rom) in individuals with cervical disc herniation, methods: thirty three participants were enrolled in the study. the patients were randomly assigned to two groups. group a received cervical-only keomt while group b received combined lumbar and cervical keomt, interventions were administered three times a week for four weeks. pain was measured using the visual analog scale (vas), rom was assessed for flexion and lateral flexion, and neck pain and disability index (npdi) and short-form 36 health survey (sf-36) were used for evaluation.


Eligibility criteria:
inclusion criteria: * diagnosed with cervical disc herniation at least 8 weeks but not more than 5 years prior. * cervical disc herniation verified by magnetic resonance imaging (mri) at 1 or 2 segmental levels, consistent with clinical findings. * neck disability index (ndi) score greater than 5. * no use of analgesic medication other than the prescribed treatment before or during the study period. exclusion criteria: * history of myelopathy, whiplash-associated disorder, generalized myalgia, malignant tumor, or inflammatory disease. * painful back problems or neurological symptoms within the past year. * psychiatric disorders or drug abuse. * contraindications to physical therapy or inability to return to work or perform physical therapy due to other diseases or disabilities. * inability to communicate effectively. * participation in any additional interventions outside the prescribed treatment during the study period.

Keywords: intervertebral disc displacement musculoskeletal manipulations range of motion articular neck pain
a randomized, double-blind, parallel-group, vehicle-controlled therapeutic equivalence study of three imiquimod cream 5% treatments for patients with actinic keratosis

Conditions: Actinic Keratosis

Summary: treatment, randomized, double blind (subject, caregiver, investigator, outcomes assessor), placebo control, parallel assignment, bio-equivalence study


Eligibility criteria:
inclusion criteria: * patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic ak lesions within a 25 cm2 contiguous treatment area on either the face or balding scalp * women either must be 1 year post-menopausal, surgically sterile, or agree to use a medically accepted form or birth control * free of any systemic or dermatological disorder * any skin type or race, providing the skin pigmentation will allow discernment of erythema exclusion criteria: * basal cell or squamous cell carcinoma, or other possible confounding skin conditions (on face and scalp) * history of cutaneous hyperreactivity or facial irritation to topical products * engaging in activities involving excessive or prolonged exposure to sunlight * receiving systemic cancer chemotherapy, psoralen plus uva therapy, uvb therapy, laser abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study entry * currently using or have used systemic steroids 2 months prior to study * currently using or have used on the treatment area over-the-counter retinol products, corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic keratosis treatments 28 days prior to randomization * pregnant or nursing mothers * history of allergy or sensitivity to imiquimod or related compounds or other components of the formulation * taking immunosuppressant medication
multi-center, open-label, 24-week study of ox219 safety and efficacy for maintenance treatment of opioid dependence

Conditions: Opioid Dependence, on Agonist Therapy

Summary: the purpose of this study was to assess safety, efficacy, and treatment retention following extended treatment with ox219, a higher-bioavailability buprenorphine/naloxone (bnx) sublingual tablet formulation in opioid-dependent patients who completed 1 of 2 primary efficacy and safety studies of ox219.

this was a multicenter, open-label, uncontrolled, single-arm, 24-week, extension study to assess safety, efficacy, and treatment retention during maintenance treatment. eligible patients had completed 1 of 2 primary efficacy and safety studies of the higher-bioavailability bnx sublingual tablet formulation (primary study ox219-006 \[nct01908842\] or ox219-007 \[nct01848054\]). the total duration of study treatment was 24 weeks.

Eligibility criteria:
inclusion criteria * signed informed consent form. * completion of 1 of 2 primary efficacy safety studies of bnx sublingual tablets (ox219-006 or ox219-007). * female patients of child bearing potential who used a reliable method of contraception (hormonal, condom with spermicide, intrauterine device) during the previous ox219-006 or ox219-007 study and continue to use it for the ox219-008 study. females who are not of child-bearing potential who are either surgically sterile (by hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or tubal ligation), or postmenopausal, as defined by being at least 50 years of age and having had an absence of menses for at least 2 years, were also eligible. exclusion criteria * females who are pregnant (positive pregnancy test result) or lactating, or planning to become pregnant during the study. * participants who are unwilling or unable to comply with the requirements of the protocol (eg, pending incarceration) or are in a situation or condition that, in the opinion of the investigator, may interfere with participation in the study. * participants who are participating in any other clinical study in which medication(s) are being delivered or who had used an investigational drug or device within the last 30 days. * participants with any known allergy or sensitivity or intolerance to buprenorphine, naloxone, or any related drug, or history of any drug hypersensitivity or intolerance that, in the opinion of the investigator, would compromise the safety of the subject or the study. * participant with a contra-indicated serious medical condition. * participants who are at suicidal risk as determined by any of the following: a history of suicidal ideation ≤ 3 months prior to baseline with a score of 4 (intent to act) or 5 (specified plan and intent) on the columbia suicide severity risk scale (c-ssrs).

Keywords: opioid, dependence, agonist, buprenorphine, naloxone
a phase 1 study of oral op-1250 in combination with palbociclib in hr+/her2- breast cancer patients

Conditions: Breast Cancer

Summary: this is an open-label, phase 1b dose escalation and expansion study to determine the maximum tolerated dose (mtd) of op-1250 in combination with palbociclib (ibrance®️, pfizer inc.). purpose of study is to evaluate the safety and pharmacokinetic (pk) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (er+ / her2-) advanced or metastatic breast cancer (mbc).


Eligibility criteria:
inclusion criteria: * confirmed and evaluable locally advanced or metastatic breast cancer * eastern cooperative oncology group (ecog) performance status of 0 or 1 * must not have received prior oral endocrine or targeted therapy ≤ 2 weeks prior to first dose * must not have received prior chemotherapy, antibody therapy, or investigational therapy ≤ 4 weeks prior to the first dose * prior radiotherapy must have been completed 2 weeks prior to first dose * adequate safety laboratory tests * willingness to use effective contraception exclusion criteria: * gastrointestinal disease * significant hepatic disease * significant cardiovascular disease * significant ecg abnormalities * history of pulmonary embolism or high risk of thrombosis * known hiv infection * active infection (requiring antimicrobial therapy) * pregnant